Migraine remains undiagnosed and undertreated in at least 50% of patients, and less than 50% of migraine patients consult a physician.1
Migraine is the third most common condition in the world, impacting an estimated 1 in 7 people worldwide.2 The financial burden of migraine is huge – it costs the UK economy an estimated £3.42 billion per year.3
AJOVY® is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month, and is the only licensed anti-CGRP therapy to offer quarterly and monthly dosing options.4
___________________________________________________________________________________________________
References:
[1] Pavone E et al. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia. 2007;27(9):1000-4
[2] https://www.migrainetrust.org/about-migraine/migraine-what-is-it/facts-figures/ [Accessed 23/07/2019]
[3] Key Facts & Figures About Migraine, The Migraine Trust
[4] AJOVY® SmPC. Teva UK Limited
To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment.
Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.